Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight with a price target of $100, down from $130. The firm sees greater risk to ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

However, 10 companies defied a broader market optimism, mostly due to a series of stock rating downgrades from investment ...

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street’s best analysts ...

Barclays downgraded Illumina Inc (NASDAQ:ILMN) to "Underweight" given growing uncertainty in China, rising competition from Roche in the clinical market, and weaker-than-expected elasticity in ...

Illumina (NASDAQ:ILMN) has been cut to underweight from equal weight by Barclays over concerns the company may be facing sanctions in China and risks to its 2025 and long-range guidance. "Given our ...

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively. We recently published a list of Jim ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Preview | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 Preview | Day 1_update | Day 2 | Day 3 | QF | SF | F Preview | Day 4 | Day 5 | SF | F WTA COVID-19 Health & Safety Protocols Summary (PDF File, ...